|
July. 28, 2026 |
|
|
July. 28, 2026 |
|
|
jRCT1050260121 |
Safety, efficacy, and treatment outcomes of no-touch endoscopic full-thickness resection for gastric submucosal tumors: a retrospective observational study |
|
A retrospective study of treatment outcomes in patients who underwent no-touch EFTR for gastric submucosal tumors |
Uedo Noriya |
||
Osaka International Cancer Institute |
||
3-1-69 Otemae Chuo-ku Osaka-shi Osaka-fu |
||
+81-6-6945-1181 |
||
noriya.uedo@gmail.com |
||
Morita Muneshin |
||
Osaka International Cancer Institute |
||
3-1-69 Otemae Chuo-ku Osaka-shi Osaka-fu |
||
+81-6-6945-1181 |
||
muneshin.m7@gmail.com |
Recruiting |
July. 28, 2026 |
||
| 38 | ||
Observational |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
Patients who underwent no-touch endoscopic full-thickness resection for gastric submucosal tumors at Osaka International Cancer Institute between July 2023 and May 2026. |
||
Patients with insufficient medical records to evaluate the primary outcome, patients judged by the investigators to be inappropriate for inclusion in this study, or patients or their representatives who declined the use of their clinical information for this study. |
||
| No limit | ||
| No limit | ||
Both |
||
Gastric submucosal tumors, including gastrointestinal stromal tumors |
||
Not applicable. This is a retrospective observational study using existing clinical information, and no intervention will be performed as part of this study. |
||
gastric submucosal tumor; gastrointestinal stromal tumor; endoscopic full-thickness resection; no-touch EFTR |
||
D018204 |
||
Histological complete resection rate (R0 resection rate), defined as the proportion of patients with histologically negative margins of the entire tumor after no-touch EFTR. |
||
Secondary outcomes include the endoscopic complete resection rate (ER0 resection rate), en bloc resection rate, time for lesion resection, time for defect closure, successful defect closure rate, postoperative adverse events, need for surgical intervention, days to resume oral intake, days to discharge, and the presence of tumor capsule injury or macroscopic tumor rupture. |
||
| none |
| Certified Review Board of Osaka International Cancer Center, Osaka Prefectural Hospital Organization (CRB5180012) | |
| 3-1-69 Otemae Chuo-ku Osaka-shi Osaka-fu, Osaka | |
+81-6-6945-1181 |
|
| rinri01@opho.jp | |
| Approval | |
July. 24, 2026 |
No |
none |